Abdessamad El Alaoui, Frédéric Schmidt, Marianne Sarr, Didier Decaudin, Jean-Claude Florent, Ludger Johannes
Index: ChemMedChem 3(11) , 1687-95, (2008)
Full Text: HTML
Peripheral benzodiazepine receptors are potential targets for cancer therapeutics through the use of specific ligands such as the pro-apoptotic benzodiazepine RO5-4864. However, the poor water solubility of this compound has been a limitation to its application in vivo. Herein we describe an efficient synthesis for the conjugation, via a cleavable linker arm, of RO5-4864 to a novel tumour-delivery tool, the B-subunit of Shiga toxin (STxB). The conjugate is water soluble and specifically targets cancer cells that overexpress the glycolipid Gb3, the cellular Shiga toxin receptor that is found on several human tumours. After internalisation via retrograde transport, the prodrug is cleaved inside cells to release the active principle. Delivery by STxB therefore increases the cytotoxic activity of RO5-4864 and its tumour specificity.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
Lyso-Globotriaosylceramide (d18:1)
CAS:126550-86-5 |
C36H67NO17 |
|
LC–MS/MS analysis of plasma lyso-Gb3 in Fabry disease
2012-12-24 [Clin. Chim. Acta 414 , 273-80, (2012)] |
|
A metabolomic study reveals novel plasma lyso-Gb3 analogs as...
2013-01-01 [Curr. Med. Chem. 20(2) , 280-8, (2013)] |
|
In vivo tumor targeting using a novel intestinal pathogen-ba...
2006-07-15 [Cancer Res. 66(14) , 7230-6, (2006)] |
|
Plasma globotriaosylsphingosine as a biomarker of Fabry dise...
2010-07-01 [Mol. Genet. Metab. 100(3) , 257-61, (2010)] |
|
Quantification of the Fabry marker lysoGb3 in human plasma b...
2012-02-01 [J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 883-884 , 128-35, (2012)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
